Kiniksa Pharmaceuticals International, plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| KNSA | BCRX | ALVO | KMDA | XERS | AKBA | |
|---|---|---|---|---|---|---|
| Market cap | 6.18B | 2.14B | 1.96B | 452.45M | 1.91B | 218.97M |
| P/E (TTM) | 79.2 | — | — | 20.1 | — | — |
| Forward P/E | 49.0 | 8.9 | 24.1 | 13.6 | 28.3 | -2.2 |
| Price/book | 9.4 | -4.7 | -10.2 | 1.7 | -186.8 | 8.6 |
| Dividend yield | — | — | — | 2.16% | — | — |
| 1-year change | +109.13% | +30.22% | −35.29% | +14.96% | +28.82% | −71.68% |
| Today | −0.68% | −2.22% | −4.84% | −2.97% | −0.19% | −1.36% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All KNSA news ›Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Consensus Target Price of $20.50 According to Analysts
Posted by Tristan Rich on Oct 2nd, 2026 View Our Latest Report on Keros Therapeutics Keros Therapeutics stock opened at $11.26 on Tuesday. The company has a market capitalization of $223.29 million, a price-to-earnings ratio of -3.04 and a…
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Coverage Initiated by Analysts at Wells Fargo & Company
Wells Fargo & Company started coverage on shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) in a research note issued to investors on Wednesday, MarketBeat reports. The brokerage set an "overweight" rating and…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketbeat.com1
-
themarketsdaily.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.